title: Clinical effects of intravenously administered dantrolene.
abstract: OBJECTIVE
  To compare side effects after intravenous administration of dantrolene sodium in subjects susceptible to and those nonsusceptible to malignant hyperthermia (MHS and MHN, respectively).
  
  
  METHODS
  We studied two groups, six patients thought to be MHS and six assumed MHN subjects, and analyzed their responses to intravenously administered dantrolene.
  
  
  METHODS
  Dantrolene (3 mg/kg) was administered slowly into an antecubital vein, and blood samples were withdrawn from the other arm at 5 and 25 minutes after infusion. Shortly thereafter, all subjects underwent a clinical neurologic assessment, and side effects were graded subjectively by the study participants.
  
  
  RESULTS
  Side effects occurred in all subjects. Visual symptoms occurred more commonly in MHN than in MHS subjects. Subjective muscle weakness of the extremities, dizziness, and fatigue occurred more commonly and were more severe in MHS patients than in MHN subjects.
  
  
  CONCLUSIONS
  In patients recovering from an episode of malignant hyperthermia for which dantrolene has been administered, these side effects should be considered. Although the presence of side effects does not outweigh the usefulness of this drug in treating malignant hyperthermia, it may be a consideration in deciding whether to administer dantrolene prophylactically before surgical procedures in known or suspected MHS patients.
authors.affiliation: Department of Anesthesiology, Mayo Clinic Rochester, MN 55905.
authors.forename: D J
authors.initials: DJ
authors.lastname: Wedel
authors.forename: J G
authors.initials: JG
authors.lastname: Quinlan
authors.forename: P A
authors.initials: PA
authors.lastname: Iaizzo
mesh_terms: D000328:Adult; D003620:Dantrolene / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004244:Dizziness / Q000139:chemically induced; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008305:Malignant Hyperthermia / Q000188:drug therapy / Q000517:prevention & control*; D008875:Middle Aged; D009132:Muscles / Q000187:drug effects; D009460:Neurologic Examination; D014785:Vision, Ocular / Q000187:drug effects
chemical_list: D003620:Dantrolene